Sign Out
There are no adequate or well-controlled studies in pregnant women. Following intranasal administration of the maximal recommended clinical dose to patients, mometasone plasma concentrations are not measurable; thus, fetal exposure is expected to be negligible and the potential for reproductive toxicity is very low.
As with other nasal corticosteroid preparations, Nasonex should not be used in pregnant women, nursing mothers or women of childbearing age unless the potential benefit justifies the potential risk to the mother, fetus or infant. Infants born of mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism.
